Les Laboratoires Servier
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Les Laboratoires Servier
Twelve new drugs are now being reviewed for potential EU marketing approval, including Servier’s vorasidenib for IDH-mutant diffuse glioma, which the company says could become the first targeted therapy for the malignant and incurable brain tumor.
Biotech entrepreneurs tend to be an optimistic group, and there were many pockets of hope for 2024. However, the consensus remains that depressed valuations and paucity of fresh funds will continue to pose a challenge for the sector, and companies will need to prioritize carefully and work even harder to demonstrate and create value.
UK liquids specialist Rosemont Pharmaceuticals has appointed a new chief corporate development officer to drive M&A. Meanwhile, EuroAPI has named a chief transformation officer, Zentiva’s CEO has joined Medicines for Europe’s executive committee, Hikma has changed company secretary, and Xbrane has made alterations to its nominations committee.
The European Medicines Agency is this week deciding whether its reviews of planned marketing applications from Rocket Pharmaceuticals and Servier merit accelerated assessment status.
- Generic Drugs
- Gene Therapy, Cell Therapy
- Other Names / Subsidiaries
- Biogaran SAS
- Egis Pharmaceuticals plc
- Servier BioInnovation
- Symphogen A/S
- Servier Pharmaceuticals, LLC.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.